with proprietary technologies (4 patents issued)
We help people live longer.
Aprimus' unlocks quantitative blood care with new chemistry technology that is more accurate, convenient, and affordable.
Our IP Portfolio - with 4 patents issued so far - protects
Our Philosophy
Aprimus' Mission and Vision is the commitment to optimize and advance personalized care by implementing innovative diagnostic and monitoring tools. Our products facilitate not only early treatment start, but also ensure optimum outcome via convenient and easy monitoring of the medication regimen.
Our People
Jack Aronowitz
Jack Aronowitz
Jack Aronowitz
Aprimus Diagnostics Inc. consists of experienced professionals and veterans in lateral flow assay diagnostics, physiology, chemistry, and regulatory compliance. The team's collective experience in the medical and pharmaceutical fields totals more than 90 years, including 15 years spent working together developing proprietary products ranging from early blood clotting to cancer detection.
Frank Kochinke
Jack Aronowitz
Jack Aronowitz
In addition, the strong background in advanced drug delivery technologies allows the Aprimus team to not only envision but also custom-tailor entrepreneurial diagnostics and drug administration monitoring products. Combining convenient, economical, early detection with the ability to monitor the effect and efficiency of potent drugs makes Aprimus unique in the field.
Our Lead products pipeline
D-Dimer
This innovative test allows addressing several multi-$B medical problems
(1) diagnosing DVT and PE
(2) monitoring patients that are medicated with blood thinners to optimize the intervention (e.g. reduce potential for bleeding).
(3) Potential new uses in Pregnancy
(4) identifying and early detection of vaccine related blood clotting problems.
Development Stage: Clinical Testing in Europe (CE Mark), awaiting funding
Tumor Markers
These tests have been designed to
(1) detect potential cancers earlier (early Detection associated with Higher Survival Rate) in a more convenient, economical and faster way and to
(2) potentially support AI driven (STARGATE) cancer medication development.
What is STARGATE AI?
Ellison: STARGATE ANNOUNCEMENT
Development Stage: Pre-clinical Testing of 8 specific Tumor Markers (Feasibility established)
Mental Health Biomarkers
These tests are designed to
(1) measure central and peripheral biomarkers to diagnose, treat, and prevent major psychiatric disorders,
(2) monitor patients that are medicated to optimize the intervention (e.g. prevent toxicity and addiction).
Development Stage: Feasibility